Evidence map›Paper›PMID 38140108›Full record

ReviewPharmaceutics2023

Cell Membrane Biomimetic Nano-Delivery Systems for Cancer Therapy.

Zhenxing Xia, Weiwei Mu, Shijun Yuan, Shunli Fu, Yongjun Liu, Na Zhang

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Recent applications of near infrared to pharmaceutical process monitoring and quality control.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2025
    Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Zhenxing XiaNMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Jinan 250012, China.
Weiwei MuNMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Jinan 250012, China.
Shijun YuanNMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Jinan 250012, China.
Shunli FuNMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Jinan 250012, China.
Yongjun LiuNMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Jinan 250012, China.
Na ZhangNMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Jinan 250012, China.
National Medical Products Administration · CNShandong University · CN

Funding

National Natural Science Foundation of China 82173757National Natural Science Foundation of China 82204295The Shandong Excellent Youth Fund ZR2022YQ76
6 · The paper itself

Abstract

Nano-delivery systems have demonstrated great promise in the therapy of cancer. However, the therapeutic efficacy of conventional nanomedicines is hindered by the clearance of the blood circulation system and the physiological barriers surrounding the tumor. Inspired by the unique capabilities of cells within the body, such as immune evasion, prolonged circulation, and tumor-targeting, there has been a growing interest in developing cell membrane biomimetic nanomedicine delivery systems. Cell membrane modification on nanoparticle surfaces can prolong circulation time, activate tumor-targeting, and ultimately improve the efficacy of cancer treatment. It shows excellent development potential. This review will focus on the advancements in various cell membrane nano-drug delivery systems for cancer therapy and the obstacles encountered during clinical implementation. It is hoped that such discussions will inspire the development of cell membrane biomimetic nanomedical systems.

Indexed as

biomimeticcancer therapycell membranenano-delivery systems

Identifiers

PMID38140108
PMCPMC10748133
OpenAlexW4389673092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.